Alkermes

ALKS · NASDAQ

$44.11+$1.14 (+2.65%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $42.97

Latest news

Press releaseOct 20, 4:00 PM ETBusiness Wire
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Press releaseOct 13, 7:00 AM ETBusiness Wire
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
NewsSep 21, 1:13 PM ETVandana Singh
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment
Press releaseSep 21, 7:00 AM ETBusiness Wire
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Press releaseSep 16, 7:00 AM ETBusiness Wire
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
Press releaseSep 10, 7:00 AM ETBusiness Wire
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
Press releaseSep 9, 8:00 AM ETBusiness Wire
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
Press releaseAug 24, 6:30 PM ETBusiness Wire
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Press releaseJul 28, 7:00 AM ETBusiness Wire
Alkermes plc Reports Second Quarter 2026 Financial Results
Press releaseJul 14, 4:00 PM ETBusiness Wire
Alkermes to Report Second Quarter Financial Results on July 28, 2026
NewsJul 13, 11:06 AM ETVandana Singh
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study
Press releaseJul 13, 7:00 AM ETBusiness Wire
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Press releaseJun 17, 4:15 PM ETBusiness Wire
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
NewsJun 15, 7:16 AM ET
Alkermes Drug Gets Orphan Status in US and Europe, Wins Rare Disease Designations for Alixorexton
Press releaseJun 15, 7:00 AM ETBusiness Wire
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Press releaseJun 4, 7:00 AM ETBusiness Wire
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Press releaseJun 3, 4:05 PM ETBusiness Wire
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Press releaseMay 26, 7:00 AM ETBusiness Wire
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Press releaseMay 21, 7:00 AM ETBusiness Wire
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
NewsMay 12, 7:11 AM ET
Alkermes Topline Results From Revitalyz Phase 3 Study Of Lumryz Extended-release Oral Suspension For Idiopathic Hypersomnia Met The Study's Primary Endpoint, Demonstrating Statistically Significant Improvements In Excessive Daytime Sleepiness Compared To Placebo; Plans To File Supplemental Application To FDA By The End Of 2026
Press releaseMay 12, 7:00 AM ETBusiness Wire
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
NewsMay 6, 1:54 PM ETAvi Kapoor
Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
NewsMay 5, 7:08 AM ET
Alkermes Q1 EPS $(0.40) Beats $(0.52) Estimate, Sales $392.911M Beat $359.848M Estimate
Press releaseMay 5, 7:00 AM ETBusiness Wire
Alkermes plc Reports First Quarter 2026 Financial Results
Press releaseApr 21, 4:05 PM ETBusiness Wire
Alkermes to Report First Quarter Financial Results on May 5, 2026
Press releaseApr 16, 7:00 AM ETBusiness Wire
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Press releaseApr 14, 7:00 AM ETBusiness Wire
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
Press releaseApr 1, 7:00 AM ETBusiness Wire
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
NewsMar 31, 9:57 AM ETAvi Kapoor
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Press releaseMar 12, 7:00 AM ETBusiness Wire
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
Press releaseMar 10, 4:00 PM ETBusiness Wire
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
NewsFeb 26, 2:01 PM ET
4 Analysts Have This To Say About Alkermes
NewsFeb 25, 7:06 AM ET
Alkermes Q4 EPS $0.29 Misses $0.33 Estimate, Sales $384.547M Beat $381.848M Estimate
NewsFeb 25, 7:06 AM ET
Alkermes Q4 Earnings Summary & Key Takeaways
Press releaseFeb 25, 7:00 AM ETBusiness Wire
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
NewsFeb 24, 12:02 PM ET
Insights into Alkermes's Upcoming Earnings
NewsJan 20, 9:02 AM ETAvi Kapoor
Jim Cramer Says Sell Super Micro — Calls A European Chipmaker 'Cheap And Good'
NewsNov 26, 12:35 PM ET
10 Health Care Stocks With Whale Alerts In Today's Session
NewsJun 17, 10:00 AM ETAvi Kapoor
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday
NewsJun 17, 9:18 AM ETAvi Kapoor
This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Alkermes to Report Third Quarter Financial Results on November 3, 2026

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Alkermes plc Reports Second Quarter 2026 Financial Results

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

Alkermes Drug Gets Orphan Status in US and Europe, Wins Rare Disease Designations for Alixorexton

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Earnings Scheduled For May 5, 2026

Alkermes Q1 EPS $(0.40) Beats $(0.52) Estimate, Sales $392.911M Beat $359.848M Estimate

Alkermes plc Reports First Quarter 2026 Financial Results

Alkermes to Report First Quarter Financial Results on May 5, 2026

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

4 Analysts Have This To Say About Alkermes

Alkermes Q4 EPS $0.29 Misses $0.33 Estimate, Sales $384.547M Beat $381.848M Estimate

Alkermes Q4 Earnings Summary & Key Takeaways

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

Insights into Alkermes's Upcoming Earnings

Jim Cramer Says Sell Super Micro — Calls A European Chipmaker 'Cheap And Good'

10 Health Care Stocks With Whale Alerts In Today's Session

Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday

This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday